X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.accesswire.com/840039/alligator-bioscience-and-aptevo-therapeutics-announce-positive-interim-data-of-dose-escalation-phase-of-algapv-527-phase-1-study-in-solid-tumor-cancers-expressing-tumor-antigen-5t4
https://www.onclive.com/view/first-line-mitazalimab-plus-chemo-continues-to-generate-responses-in-metastatic-pdac
https://www.accesswire.com/739053/Alligator-Bioscience-Aptevo-Therapeutics-Announce-Dosing-of-First-Patient-with-ALGAPV-527-in-Phase-1-Clinical-Trial
https://www.pharmatimes.com/news/orion_and_alligator_reveal_second_stage_of_immuno-oncology_research_collaboration_1484909
https://pipelinereview.com/index.php/2023010282392/Antibodies/Alligator-Bioscience-Announces-Positive-Interim-Results-from-Mitazalimab-OPTIMIZE-1-Phase-2-Trial-in-Pancreatic-Cancer-Exceeding-50-Objective-Response-Rate.html
https://www.accesswire.com/724710/Alligator-Bioscience-Aptevo-Therapeutics-Announce-Publication-Highlighting-ALGAPV-527-Preclinical-Data-in-Peer-Reviewed-Journal-Molecular-Cancer-Therapeutics
https://alligatorbioscience.se/en/news/alligator-bioscience-announces-ind-approval-for-second-phase-2-clinical-trial-of-ac101-hlx22-in-gastric-cancer-developed-by-shanghai-henlius-biotech-in-china/
https://www.pharmatimes.com/news/alligator_bioscience_announces_positive_safety_data_from_ator-1017_study_1456132
https://www.accesswire.com/716405/Alligator-Bioscience-and-Aptevo-Therapeutics-Announce-that-FDA-has-Issued-a-May-Proceed-Notification-for-the-ALGAPV-527-IND
https://storage.mfn.se/52c40d2e-f8da-49b6-a418-5aee0e895a50/alligator-bioscience-presents-additional-data-from-mitazalimab-optimize-1-phase-1b-2-trial-at-aacr-special-conference-on-pancreatic-cancer-2022.pdf
Market Place
Share 
